Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

Affiliations

• ¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA. Nowakowski.Grzegorz@mayo.edu.
• ² Department of Oncology, Asan Medical Center, Songpa‑gu, Seoul, South Korea.
• ³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁴ Department of Oncology, University of Alberta, Edmonton, AB, Canada.
• ⁵ Maisonneuve‑Rosemont Hospital, Institute of Hematology, Oncology and Cell Therapy, Montreal University, Montreal, Canada.
• ⁶ Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT, and Cancer Cluster Salzburg, Salzburg, Austria.
• ⁷ Department of Haematology, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia.
• ⁸ University Hospital Freiburg Internal Medicine I, Freiburg im Breisgau, Germany.
• ⁹ University of Utah, Salt Lake City, UT, USA.
• ¹⁰ University of Illinois at Chicago, Chicago, IL, USA.
• ¹¹ IRCCS Azienda Ospedaliero‑Universitaria di Bologna, Istituto Di Ematologia "Seragnoli", Bologna, Italy.
• ¹² Dipartimento Di Medicina Specialistica, Diagnostica E Sperimentale, Universita Di Bologna, Bologna, Italy.
• ¹³ Haematology Department, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.
• ¹⁴ Incyte Biosciences International Sarl, Morges, Switzerland.
• ¹⁵ MorphoSys AG, Planegg, Germany.
• ¹⁶ MorphoSys AG, Boston, MA, USA.
• ¹⁷ Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IISFJD, Madrid, Spain.
• ¹⁸ Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University Mainz, Mainz, Germany.